Experience

Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering of 6,250,000 ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised the initial purchasers in connection with a $500 million offering of 7.000% senior notes due 2026 by JBS Investments II GmbH and guaranteed by JBS S.A., which were…

Davis Polk is advising Mitsubishi UFJ Lease & Finance Co., Ltd. (“MUL”) on its acquisition of ENGS Holdings Inc. from a group of shareholders represented by Aquiline Capital Partners…

Davis Polk advised the joint book-runners and representatives of the underwriters on an SEC-registered offering by Fluor Corporation of $600 million aggregate principal amount of its 4…

Davis Polk advised Auris Medical Holding AG on a public offering of common shares and warrants. The common shares are listed on the NASDAQ Global Market under the symbol “EARS.” Auris…

Davis Polk advised the representatives of the underwriters on the SEC-registered initial public offering by Uxin Limited of 25,000,000 American Depositary Shares, each representing…

Davis Polk advised the sole bookrunner in connection with an offering by PerkinElmer, Inc. of €300 million aggregate principal amount of its 0.600% notes due 2021. Headquartered in…

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 4,255,000 shares of common stock of NMI…

Davis Polk advised the underwriter in connection with the SEC-registered offering of 4,179,678 shares of common stock of OneMain Holdings, Inc. sold by Springleaf Financial Holdings, LLC on…